

Immunregulation durch regulatorische T-Zellen

Immuno-régulation par les lymphocytes T régulateurs

Literatur / Références

1. Waldmann, T.A., et al., Disorders of suppressor immunoregulatory cells in the pathogenesis of immunodeficiency and autoimmunity. *Ann Intern Med*, 1978. 88(2): p. 226–38.
2. Maloy, K.J. and F. Powrie, Regulatory T cells in the control of immune pathology. *Nat Immunol*, 2001. 2(9): p. 816–22.
3. Powell, B.R., N.R. Buist, and P. Stenzel, An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. *J Pediatr*, 1982. 100(5): p. 731–7.
4. Brunkow, M.E., et al., Disruption of a new forkhead/winged-helix protein, scurfy, results in the fatal lymphoproliferative disorder of the scurfy mouse. *Nat Genet*, 2001. 27(1): p. 68–73.
5. Wildin, R.S., et al., X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. *Nat Genet*, 2001. 27(1): p. 18–20.
6. Torgerson, T.R. and H.D. Ochs, Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. *J Allergy Clin Immunol*, 2007. 120(4): p. 744–50; quiz 751–2.
7. Kinnunen, T., et al., Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. *Blood*, 2013. 121(9): p. 1595–603.
8. Costantino, C.M., C.M. Baecher-Allan, and D.A. Hafler, Human regulatory T cells and autoimmunity. *Eur J Immunol*, 2008. 38(4): p. 921–4.
9. Rosenberg, S.A., Raising the bar: the curative potential of human cancer immunotherapy. *Sci Transl Med*, 2012. 4(127): p. 127ps8.
10. Jacobs, J.F., et al., Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? *Lancet Oncol*, 2012. 13(1): p. e32–42.
11. Curiel, T.J., et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med*, 2004. 10(9): p. 942–9.
12. Knol, A.C., et al., Prognostic value of tumor-infiltrating Foxp3+ T-cell subpopulations in metastatic melanoma. *Exp Dermatol*, 2011. 20(5): p. 430–4.
13. Quezada, S.A., et al., CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. *J Clin Invest*, 2006. 116(7): p. 1935–45.
14. Onizuka, S., et al., Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. *Cancer Res*, 1999. 59(13): p. 3128–33.
15. Riley, J.L., C.H. June, and B.R. Blazar, Human T regulatory cell therapy: take a billion or so and call me in the morning. *Immunology*, 2009. 30(5): p. 656–65.
16. Singer, B.D., L.S. King, and F.R. D'Alessio, Regulatory T cells as immunotherapy. *Front Immunol*, 2014. 5: p. 46.
17. Yee, C., The use of endogenous T cells for adoptive transfer. *Immunol Rev*, 2014. 257(1): p. 250–63.
18. Miyara, M., K. Wing, and S. Sakaguchi, Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. *J Allergy Clin Immunol*, 2009. 123(4): p. 749–55; quiz 756–7.
19. Di Ianni, M., et al., Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. *Blood*, 2011. 117(14): p. 3921–8.
20. Sugiyama, D., et al., Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. *Proc Natl Acad Sci U S A*, 2013. 110(44): p. 17945–50.
21. Trzonkowski, P., et al., First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127– T regulatory cells. *Clin Immunol*, 2009. 133(1): p. 22–6.
22. Brunstein, C.G., et al., Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. *Blood*, 2011. 117(3): p. 1061–70.
23. Marek-Trzonkowska, N., et al., Administration of CD4+CD25highCD127– regulatory T cells preserves beta-cell function in type 1 diabetes in children. *Diabetes Care*, 2012. 35(9): p. 1817–20.
24. Leslie, M., Regulatory T Cells Get Their Chance to Shine. *Science*, 2011. 332: p. 1020.
25. Shevach, E.M., Application of IL-2 therapy to target T regulatory cell function. *Trends Immunol*, 2012. 33(12): p. 626–32.
26. Rosenberg, S.A. and M.T. Lotze, Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. *Annu Rev Immunol*, 1986. 4: p. 681–709.
27. Liston, A. and D.H. Gray, Homeostatic control of regulatory T cell diversity. *Nat Rev Immunol*, 2014. 14(3): p. 154–65.
28. Saadoun, D., et al., Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. *N Engl J Med*, 2011. 365(22): p. 2067–77.
29. Hartemann, A., et al., Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol*, 2013. 1(4): p. 295–305.

30. Ozdemir, C., et al., Specific immunotherapy and turning off the T cell: how does it work? *Ann Allergy Asthma Immunol*, 2011. 107(5): p. 381–92.
31. Gallimore, A. and S. Sakaguchi, Regulation of tumour immunity by CD25+ T cells. *Immunology*, 2002. 107(1): p. 5–9.
32. Golovina, T.N. and R.H. Vonderheide, Regulatory T cells: overcoming suppression of T-cell immunity. *Cancer J*, 2010. 16(4): p. 342–7.
33. Jacobs, J.F., et al., Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. *Clin Cancer Res*, 2010. 16(20): p. 5067–78.
34. Powell, D.J., Jr., et al., Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. *J Immunol*, 2007. 179(7): p. 4919–28.
35. Hodi, F.S., et al., Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med*, 2010. 363(8): p. 711–23.
36. Beyersdorf, N., et al., Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. *J Exp Med*, 2005. 202(3): p. 445–55.
37. Lin, C.H. and T. Hunig, Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. *Eur J Immunol*, 2003. 33(3): p. 626–38.
38. Suntharalingam, G., et al., Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. *N Engl J Med*, 2006. 355(10): p. 1018–28.
39. Boyman, O., et al., Selective stimulation of T cell subsets with antibody-cytokine immune complexes. *Science*, 2006. 311(5769): p. 1924–7.
40. Boyman, O. and J. Sprent, The role of interleukin-2 during homeostasis and activation of the immune system. *Nat Rev Immunol*, 2012. 12(3): p. 180–90.
41. Lahl, K., et al., Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. *J Exp Med*, 2007. 204(1): p. 57–63.
42. Christiaansen, A.F., P.M. Boggiatto, and S.M. Varga, Limitations of Foxp3(+) Treg depletion following viral infection in DREG mice. *J Immunol Methods*, 2014. 406: p. 58–65.
43. Marek-Trzonkowska, N., et al., Clinical application of regulatory T cells in type 1 diabetes. *Pediatr Diabetes*, 2013. 14(5): p. 322–32.
44. Meignin, V., et al., Numbers of Foxp3-expressing CD4+CD25high T cells do not correlate with the establishment of long-term tolerance after allogeneic stem cell transplantation. *Exp Hematol*, 2005. 33(8): p. 894–900.
45. Sanchez, J., et al., Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation. *Br J Haematol*, 2004. 126(5): p. 697–703.
46. Clark, F.J., et al., Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. *Blood*, 2004. 103(6): p. 2410–6.
47. Zorn, E., et al., Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. *Blood*, 2005. 106(8): p. 2903–11.
48. Liu, B., et al., Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. *Eur J Haematol*, 2007. 78(2): p. 139–43.
49. Shi, J., et al., Intrinsic impairment of CD4(+)CD25(+) regulatory T cells in acquired aplastic anemia. *Blood*, 2012. 120(8): p. 1624–32.
50. Lee, H.Y., et al., Altered frequency and migration capacity of CD4+CD25+ regulatory T cells in systemic lupus erythematosus. *Rheumatology (Oxford)*, 2008. 47(6): p. 789–94.
51. Zhang, B., et al., Clinical significance of increased CD4+CD25–Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. *Ann Rheum Dis*, 2008. 67(7): p. 1037–40.
52. Miyara, M., et al., Global natural regulatory T cell depletion in active systemic lupus erythematosus. *J Immunol*, 2005. 175(12): p. 8392–400.
53. Banica, L., et al., Quantification and molecular characterization of regulatory T cells in connective tissue diseases. *Autoimmunity*, 2009. 42(1): p. 41–9.
54. van Amelsfort, J.M., et al., CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. *Arthritis Rheum*, 2004. 50(9): p. 2775–85.
55. Venken, K., et al., Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. *J Neurosci Res*, 2006. 83(8): p. 1432–46.
56. Putheti, P., et al., Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. *J Clin Immunol*, 2004. 24(2): p. 155–61.
57. Wang, Y., et al., Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. *J Dig Dis*, 2011. 12(4): p. 286–94.
58. Eastaff-Leung, N., et al., Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. *J Clin Immunol*, 2010. 30(1): p. 80–9.
59. Boyer, O., et al., CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. *Blood*, 2004. 103(9): p. 3428–30.
60. Martelli, M.F., et al., HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. *Blood*, 2014. 124(4): p. 638–44.
61. Kennedy-Nasser, A.A., et al., Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. *Clin Cancer Res*, 2014. 20(8): p. 2215–25.
62. Matsuoka, K., et al., Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. *Sci Transl Med*, 2013. 5(179): p. 179ra43.
63. Koreth, J., et al., Interleukin-2 and regulatory T cells in graft-versus-host disease. *N Engl J Med*, 2011. 365(22): p. 2055–66.
64. Long, S.A., et al., Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. *Diabetes*, 2012. 61(9): p. 2340–8.
65. Bohle, B., et al., Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. *J Allergy Clin Immunol*, 2007. 120(3): p. 707–13.
66. Powell, D.J., Jr., et al., Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. *J Immunother*, 2008. 31(2): p. 189–98.